- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03799614
Vibration Impact on Parkinson's Tremor
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Parkinson's disease (PD) as diagnosed by a movement disorder specialist
- Tremor caused by their Parkinson's disease
- Ability to provide informed consent
Exclusion Criteria:
- Known diagnosis of Parkinson Plus Syndrome
- Dementia
- Other known non-PD cause of tremor
- Other known non-PD cause of limb dysfunction
- Presence of implantable cardiac device, severe neuropathy or sensory loss that would prevent perception of vibration stimulus
- Non-English speaker
- Prisoners
- Pregnant women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lower dose vibration
RMBand lower dose vibration
|
Light-weight portable device that delivers low dose vibration to the arm
|
Experimental: Higher dose vibration
RMBand higher dose vibration
|
Light-weight portable device that delivers higher dose vibration to the arm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS)
Time Frame: This rating scale will be used at baseline, 5 minutes after vibration starts, and 5 minutes after vibration is turned off.
|
The "Movement Disorder Society Unified Parkinson Disease Rating Scale" (MDS-UPDRS) Part III, only, will be used at baseline, and repeated during vibration and post vibration data collection times.
It is a validated scale administered by a clinician, contains 34 items to score between 0 (normal) and 4 (severe).
The score range is 0 - 136.
It takes ~ 5 minutes to complete.
Lower scores are better.
This outcome measure will be used to report a change in PD motor symptoms over time.
|
This rating scale will be used at baseline, 5 minutes after vibration starts, and 5 minutes after vibration is turned off.
|
Clinical Rating for Tremor
Time Frame: Data collection times were baseline, 5 minutes after vibration start (vibration duration was 20 minutes), 5 minutes after vibration was stopped. .
|
Clinical Rating Scale for Tremor (Fahn, Tolosa, & Marin) assesses severity of tremor symptoms. This scale takes 10-minutes, Items 1 - 14 will be used to report average changes in tremor. Items are rated on a scale of 0=normal to 4=severely abnormal, total summative score range for items 1- 14 points is 0 - 56. Lower scores are better. Total time to complete the Scale for Tremor assessment is 10 minutes. |
Data collection times were baseline, 5 minutes after vibration start (vibration duration was 20 minutes), 5 minutes after vibration was stopped. .
|
Objective Measurement of Tremor Frequency (Hz)
Time Frame: Five minutes before vibration is turned on, throughout vibration treatment, and approximately five minutes post treatment.
|
This is a device that will objectively measure tremors frequency and amplitude pre, during, and post treatment.
|
Five minutes before vibration is turned on, throughout vibration treatment, and approximately five minutes post treatment.
|
Objective Measurement of Tremor Amplitude (mm).
Time Frame: Five minutes before vibration is turned on, throughout vibration treatment, and approximately five minutes post treatment.
|
This is a device that will objectively measure tremor amplitude pre, during, and post treatment.
|
Five minutes before vibration is turned on, throughout vibration treatment, and approximately five minutes post treatment.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ingrid Pretzer-Aboff, PhD, RN, Virginia Commonwealth University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HM20012404
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on RMBand lower dose
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingPrimary Immune ThrombocytopeniaChina
-
Jennifer Gassman, PhDNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); The...CompletedChronic Kidney DiseaseUnited States
-
Jiangsu Kanion Pharmaceutical Co., LtdCompleted
-
HealthCore-NERINational Heart, Lung, and Blood Institute (NHLBI); Transfusion Medicine/Hemostasis...CompletedThrombocytopeniaUnited States
-
Population Health Research InstituteRecruitingCardiovascular Diseases | Percutaneous Coronary InterventionCanada
-
Azidus BrasilCellavita Pesquisa Científica Ltda; Azidus Brasil Scientific Research and Development...Active, not recruiting
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompletedDifferentiated Thyroid CancerChina
-
Novartis PharmaceuticalsWithdrawnPrimary Sjögren's Syndrome
-
The University of Texas Health Science Center,...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingAutism Spectrum Disorder | Gastrointestinal SymptomsUnited States